Overview

* Personalis Q2 2025 revenue drops 24%, missing analyst expectations, per LSEG data

* Company reports 59% sequential growth in clinical test volume for Q2

* Personalis ( PSNL ) expands Tempus AI partnership to include colorectal cancer

Outlook

* Personalis ( PSNL ) expects Q3 revenue between $12.0 mln and $14.0 mln

* Company sees full-year revenue at $70 mln to $80 mln

* Personalis ( PSNL ) anticipates Q3 pharma tests revenue of $11.0 mln to $13.0 mln

* Company expects full-year gross margin of 22% to 24%

Result Drivers

* CLINICAL TEST VOLUME - 59% sequential growth in clinical test volume driven by physician adoption of NeXT Personal platform

* PARTNERSHIP EXPANSION - Expanded collaboration with Tempus AI to include colorectal cancer, aiming to capture new market

* CLINICAL EVIDENCE - Presented pivotal data at ASCO showing NeXT Personal's ability to predict therapy response in breast cancer

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Miss $17.20 $20.10

Revenue mln mln (7

Analysts

)

Q2 EPS -$0.23

Q2 Net -$20.06

Income mln

Q2 Basic -$0.23

EPS

Q2 -$21.80

Income mln

From

Operatio

ns

Q2 -$20.05

Pretax mln

Profit

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for Personalis Inc ( PSNL ) is $7.50, about 25.7% above its August 4 closing price of $5.57

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)